Unique Imaging Findings of Neurologic Phantosmia Following Pfizer-BioNtech COVID-19 Vaccination: A Case Report
- PMID: 34096896
- DOI: 10.1097/RMR.0000000000000287
Unique Imaging Findings of Neurologic Phantosmia Following Pfizer-BioNtech COVID-19 Vaccination: A Case Report
Abstract
Olfactory dysfunction related to SARS-CoV-2 infection and COVID-19 disease is now well established in the literature. In December 2020, the FDA approved the Pfizer-BioNTech and Moderna vaccines for use in preventing COVID-19 in the United States. To the best of our knowledge, this is the first report of a phantosmia post-Pfizer COVID-19 vaccination, with positive magnetic resonance imaging radiographic findings in a patient with documented absence of infection by SARS-CoV-2 virus or concomitant sinonasal disease.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Tong JY, Wong A, Zhu D, et al. The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis. Otolaryngol Head Neck Surg 2020; 163:3–11.
-
- Xydakis MS, Dehgani-Mobaraki P, Holbrook EH, et al. Smell and taste dysfunction in patients with COVID-19. Lancet Infect Dis 2020; 20:1015–1016.
-
- Whitcroft KL, Hummel T. Olfactory dysfunction in COVID-19: diagnosis and management. JAMA 2020; 323:2512–2514.
-
- Kirschenbaum D, Imbach LL, Ulrich S, et al. Inflammatory olfactory neuropathy in two patients with COVID-19. Lancet 2020; 396:166.
-
- Lee Y, Min P, Lee S, et al. Prevalence and duration of acute loss of smell or taste in COVID-19 patients. J Korean Med Sci 2020; 35:e174.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous